These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 10263719)

  • 1. Product selection, bioequivalence, and therapeutic equivalence: the generic drug market.
    Halperin JA
    Drug Inf J; 1983; 17(2):73-6. PubMed ID: 10263719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioequivalence of generic thioridazine drug products--the FDA viewpoint.
    Hamrell MR; Martinez MN; Dighe SV; Parkman PD
    Drug Intell Clin Pharm; 1987 Apr; 21(4):362-72. PubMed ID: 3569040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A generic drug primer: regulatory aspects and scientific concepts.
    Henderson JD; White GL
    Mil Med; 1998 Apr; 163(4):193-7. PubMed ID: 9575760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulating Generic Ophthalmologic Drug Bioequivalence-Envisioning Accessibility for Patients.
    Luke MC; Kozak D
    J Ocul Pharmacol Ther; 2021 Apr; 37(3):157-161. PubMed ID: 33332225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations.
    Knoben JE; Scott GR; Tonelli RJ
    Am J Hosp Pharm; 1990 Dec; 47(12):2696-700. PubMed ID: 2278285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Community pharmacists' understanding and perceptions of FDA therapeutic equivalence standards.
    Euen BJ; Fadda HM
    Res Social Adm Pharm; 2019 Jan; 15(1):77-83. PubMed ID: 29567088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common deficiencies with bioequivalence submissions in abbreviated new drug applications assessed by FDA.
    Liu Q; Davit BM; Cherstniakova SA; Dandamudi S; Walters JF; Lee CH; Raines KW; Ren K; Williamson LN; Conner DP
    AAPS J; 2012 Mar; 14(1):19-22. PubMed ID: 22130775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generic drug product equivalence: current status.
    Meyer MC
    Am J Manag Care; 1998 Aug; 4(8):1183-9; quiz 1190-2. PubMed ID: 10182892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addressing the Regulatory and Scientific Challenges with Generic Orally Inhaled Drug Products.
    Newman B; Witzmann K
    Pharmaceut Med; 2020 Apr; 34(2):93-102. PubMed ID: 32112304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic inequivalence.
    Rheinstein PH
    Drug Saf; 1990; 5 Suppl 1():114-9. PubMed ID: 2182054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC
    J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory aspects of modifications to innovator bronchodilator metered dose inhalers and development of generic substitutes.
    Adams WP; Poochikian G; Taylor AS; Patel RM; Burke GP; Williams RL
    J Aerosol Med; 1994; 7(2):119-34. PubMed ID: 10147277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generic drugs and the prescribing physician.
    Nightingale SL; Morrison JC
    JAMA; 1987 Sep; 258(9):1200-4. PubMed ID: 3626003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the safety of generic drugs.
    Dighe SV
    Transplant Proc; 1999 May; 31(3A Suppl):23S-24S. PubMed ID: 10330955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA critical path initiatives: opportunities for generic drug development.
    Lionberger RA
    AAPS J; 2008; 10(1):103-9. PubMed ID: 18446510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scientific Considerations for the Review and Approval of First Generic Mometasone Furoate Nasal Suspension Spray in the United States from the Bioequivalence Perspective.
    Liu Q; Absar M; Saluja B; Guo C; Chowdhury B; Lionberger R; Conner DP; Li BV
    AAPS J; 2019 Jan; 21(2):14. PubMed ID: 30617594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generic substitution: issues for problematic drugs.
    Henderson JD; Esham RH
    South Med J; 2001 Jan; 94(1):16-21. PubMed ID: 11213935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
    Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
    PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generics and cost-effective prescribing in Belgium: does bioequivalence always translate in therapeutic equivalence?
    Dupont AG; Heller F
    Acta Clin Belg; 2009; 64(5):406-14. PubMed ID: 19999388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.